NCT04637269

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

Anti-BCMA CAR-T Cell Therapy for the Relapsed or Refractory Multiple Myeloma: a Multi-center, Uncontrolled Trial.

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Xinqiao Hospital of Chongqing · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are few effective treatments for MM(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell therapy for patients with relapsed and refractory multiple myeloma.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	anti-BCMA CAR-T	5×10\^7 /KG 15×10\^7 /KG 45×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.

Timeline

• Start date: 2020-11-17
• Primary completion: 2021-11-01
• Completion: 2023-11-01
• First posted: 2020-11-19
• Last updated: 2020-11-19

Locations

1 site across 1 country: China